{"id":139231,"date":"2026-07-03T16:09:57","date_gmt":"2026-07-03T10:39:57","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=139231"},"modified":"2026-07-03T16:09:59","modified_gmt":"2026-07-03T10:39:59","slug":"piramal-pharma-q1-results-2027-preview","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/","title":{"rendered":"Piramal Pharma Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Piramal Pharma CMP Rs.168. Q1 FY27E revenue Rs.1,854-2,133 Cr. PAT estimate Rs.-36&#8211;46 Cr. 12-month target Rs.160-182.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/pplpharma\/piramal-pharma-ltd-share-price-today\">Piramal Pharma<\/a> Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Piramal Pharma shares trading at Rs.168 against a market capitalisation of Rs.22,393 Cr and a price-to-earnings multiple of Not meaningful. As a pharmaceuticals and life sciences name on the NSE and BSE, Piramal Pharma enters the Piramal Pharma Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.<\/p>\n<p>This Piramal Pharma Q1 Results FY27 preview is built on a trailing-growth framework applied to the company&#8217;s Q1 FY26 base of Rs.1,992 Cr revenue and Rs.-82 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company&#8217;s own guidance once released.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=piramal-pharma-q1-fy27\"><strong>Get Free Investment Predictions and Piramal Pharma Research at Univest<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#About_Piramal_Pharma\" title=\"About Piramal Pharma\">About Piramal Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#Piramal_Pharma_Q1_FY27_Estimates\" title=\"Piramal Pharma Q1 FY27 Estimates\">Piramal Pharma Q1 FY27 Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#Key_Catalysts_to_Watch\" title=\"Key Catalysts to Watch\">Key Catalysts to Watch<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#1_CDMO_Pipeline_Visibility\" title=\"1. CDMO Pipeline Visibility\">1. CDMO Pipeline Visibility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#2_New_Product_Approvals\" title=\"2. New Product Approvals\">2. New Product Approvals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#3_Capacity_Scale-Up\" title=\"3. Capacity Scale-Up\">3. Capacity Scale-Up<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#Key_Risks_to_the_Piramal_Pharma_Q1_Results_FY27_Outlook\" title=\"Key Risks to the Piramal Pharma Q1 Results FY27 Outlook\">Key Risks to the Piramal Pharma Q1 Results FY27 Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#Q4_FY26_Performance_Context_for_the_Piramal_Pharma_Q1_Results_FY27_Print\" title=\"Q4 FY26 Performance Context for the Piramal Pharma Q1 Results FY27 Print\">Q4 FY26 Performance Context for the Piramal Pharma Q1 Results FY27 Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#Technical_Analysis_Ahead_of_Piramal_Pharma_Q1_Results_FY27\" title=\"Technical Analysis Ahead of Piramal Pharma Q1 Results FY27\">Technical Analysis Ahead of Piramal Pharma Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#Share_Price_Target_Based_on_the_Piramal_Pharma_Q1_Results_FY27_Outlook\" title=\"Share Price Target Based on the Piramal Pharma Q1 Results FY27 Outlook\">Share Price Target Based on the Piramal Pharma Q1 Results FY27 Outlook<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#3-6_Month_Target\" title=\"3-6 Month Target\">3-6 Month Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#12-Month_Target\" title=\"12-Month Target\">12-Month Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#FY27-28_Outlook\" title=\"FY27-28 Outlook\">FY27-28 Outlook<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#What_to_Watch_in_the_Piramal_Pharma_Q1_Results_FY27_Print\" title=\"What to Watch in the Piramal Pharma Q1 Results FY27 Print\">What to Watch in the Piramal Pharma Q1 Results FY27 Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#Conclusion_on_Piramal_Pharma_Q1_Results_FY27\" title=\"Conclusion on Piramal Pharma Q1 Results FY27\">Conclusion on Piramal Pharma Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#FAQs_on_Piramal_Pharma_Q1_Results_FY27\" title=\"FAQs on Piramal Pharma Q1 Results FY27\">FAQs on Piramal Pharma Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#When_are_Piramal_Pharma_Q1_FY27_results_expected\" title=\"When are Piramal Pharma Q1 FY27 results expected?\">When are Piramal Pharma Q1 FY27 results expected?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#What_is_the_Piramal_Pharma_Q1_FY27_revenue_estimate\" title=\"What is the Piramal Pharma Q1 FY27 revenue estimate?\">What is the Piramal Pharma Q1 FY27 revenue estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#What_is_the_Piramal_Pharma_share_price_target\" title=\"What is the Piramal Pharma share price target?\">What is the Piramal Pharma share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#Is_Piramal_Pharma_a_good_buy_before_Q1_FY27_results\" title=\"Is Piramal Pharma a good buy before Q1 FY27 results?\">Is Piramal Pharma a good buy before Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#What_should_investors_watch_in_Piramal_Pharmas_Q1_FY27_results\" title=\"What should investors watch in Piramal Pharma&#8217;s Q1 FY27 results?\">What should investors watch in Piramal Pharma&#8217;s Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q1-results-2027-preview\/#Where_can_I_track_Piramal_Pharma_share_price_live\" title=\"Where can I track Piramal Pharma share price live?\">Where can I track Piramal Pharma share price live?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"About_Piramal_Pharma\"><\/span><strong>About Piramal Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Piramal Pharma (NSE: PPLPHARMA) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings. Ahead of the Piramal Pharma Q1 Results FY27 print, the company&#8217;s Q4 FY26 base shows revenue of Rs.2,798 Cr and net profit of Rs.-9 Cr, forming the base against which the Piramal Pharma Q1 Results FY27 estimates in this article are built. This Piramal Pharma Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company&#8217;s own disclosures.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Q1_FY27_Estimates\"><\/span><strong>Piramal Pharma Q1 FY27 Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse;\">\n<thead>\n<tr style=\"background: #F0F2F5;\">\n<th style=\"padding: 8px; text-align: left; border: 1px solid #DDD;\">Metric<\/th>\n<th style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">Q1 FY27E (Range)<\/th>\n<th style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">Q1 FY26 Actual<\/th>\n<th style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">YoY Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Revenue (Rs. Cr)<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">1,854-2,133<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">1,992<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">+0.1%<\/td>\n<\/tr>\n<tr style=\"background: #FFFFFF;\">\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Net Profit \/ PAT (Rs. Cr)<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">-36&#8211;46<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">-82<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">-50.0%<\/td>\n<\/tr>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Results Date<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\" colspan=\"3\">July-August 2026 (indicative)<\/td>\n<\/tr>\n<tr style=\"background: #FFFFFF;\">\n<td style=\"padding: 8px; border: 1px solid #DDD;\">12-Month Target (Uniresearch Estimate)<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\" colspan=\"3\">Rs.160-182<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Univest, a SEBI-Registered Investment Advisor, Tracks Piramal Pharma Ahead of Q1 FY27 Results<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Catalysts_to_Watch\"><\/span><strong>Key Catalysts to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_CDMO_Pipeline_Visibility\"><\/span><strong>1. CDMO Pipeline Visibility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility is one of the primary variables that analysts are tracking ahead of Piramal Pharma&#8217;s Q1 FY27 results and FY27 guidance. The market&#8217;s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Piramal Pharma share price target or faces renewed pressure.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_New_Product_Approvals\"><\/span><strong>2. New Product Approvals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>New product approvals and launches adding to the domestic and export portfolio is one of the primary variables that analysts are tracking ahead of Piramal Pharma&#8217;s Q1 FY27 results and FY27 guidance. The market&#8217;s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Piramal Pharma share price target or faces renewed pressure.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Capacity_Scale-Up\"><\/span><strong>3. Capacity Scale-Up<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Operating leverage from scale-up in recently commissioned manufacturing capacity is one of the primary variables that analysts are tracking ahead of Piramal Pharma&#8217;s Q1 FY27 results and FY27 guidance. The market&#8217;s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Piramal Pharma share price target or faces renewed pressure.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Piramal Pharma&#8217;s live price and Q1 FY27 result updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Piramal_Pharma_Q1_Results_FY27_Outlook\"><\/span><strong>Key Risks to the Piramal Pharma Q1 Results FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Pricing pressure in key export markets, particularly the US generics segment.<\/li>\n<li>Regulatory or plant compliance issues affecting supply continuity.<\/li>\n<li>R&amp;D and capacity expansion costs weighing on near-term profitability.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Q4_FY26_Performance_Context_for_the_Piramal_Pharma_Q1_Results_FY27_Print\"><\/span><strong>Q4 FY26 Performance Context for the Piramal Pharma Q1 Results FY27 Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Piramal Pharma closed Q4 FY26 with revenue of Rs.2,798 Cr and net profit of Rs.-9 Cr, a year-on-year revenue change of +0.1% and PAT change of -105.8%. This base underpins the Piramal Pharma Q1 Results FY27 projection used in this preview and should be read alongside the company&#8217;s own Piramal Pharma Q1 Results FY27 commentary once reported.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Analysis_Ahead_of_Piramal_Pharma_Q1_Results_FY27\"><\/span><strong>Technical Analysis Ahead of Piramal Pharma Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Piramal Pharma shares last traded at Rs.168. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Share_Price_Target_Based_on_the_Piramal_Pharma_Q1_Results_FY27_Outlook\"><\/span><strong>Share Price Target Based on the Piramal Pharma Q1 Results FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"3-6_Month_Target\"><\/span><strong>3-6 Month Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Over a 3-6 month horizon, the Piramal Pharma Q1 Results FY27 trailing-growth framework points to a range of Rs.162-175 for Piramal Pharma, contingent on the Piramal Pharma Q1 Results FY27 print matching or beating the trailing growth trend.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12-Month_Target\"><\/span><strong>12-Month Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month target (Uniresearch estimate) tied to this Piramal Pharma Q1 Results FY27 view for Piramal Pharma works out to Rs.160-182, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Piramal Pharma Q1 Results FY27, not a formal Buy or Sell call.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FY27-28_Outlook\"><\/span><strong>FY27-28 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Piramal Pharma Q1 Results FY27 analysis would put Piramal Pharma in a Rs.164-194 range, though this is sensitive to sector-wide demand, cost trends and any change in the company&#8217;s competitive position.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_in_the_Piramal_Pharma_Q1_Results_FY27_Print\"><\/span><strong>What to Watch in the Piramal Pharma Q1 Results FY27 Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Revenue and PAT versus the Piramal Pharma Q1 Results FY27 estimate range in this preview.<\/li>\n<li>Management commentary on FY27 growth guidance and margin trajectory relevant to the Piramal Pharma Q1 Results FY27 narrative.<\/li>\n<li>Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility<\/li>\n<li>Pricing pressure in key export markets, particularly the US generics segment<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_on_Piramal_Pharma_Q1_Results_FY27\"><\/span><strong>Conclusion on Piramal Pharma Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Piramal Pharma enters the Q1 FY27 results season trading at Rs.168, with the 12-month Uniresearch target range of Rs.160-182 reflecting a tracking stance. Investors tracking the Piramal Pharma Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Piramal_Pharma_Q1_Results_FY27\"><\/span><strong>FAQs on Piramal Pharma Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_are_Piramal_Pharma_Q1_FY27_results_expected\"><\/span><strong>When are Piramal Pharma Q1 FY27 results expected?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. Piramal Pharma&#8217;s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Piramal_Pharma_Q1_FY27_revenue_estimate\"><\/span><strong>What is the Piramal Pharma Q1 FY27 revenue estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. The Uniresearch trailing-growth estimate for Piramal Pharma&#8217;s Q1 FY27 revenue is Rs.1,854-2,133 Cr, based on the Q1 FY26 base of Rs.1,992 Cr.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Piramal_Pharma_share_price_target\"><\/span><strong>What is the Piramal Pharma share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. The 12-month Uniresearch estimate for Piramal Pharma share price target is Rs.160-182, based on trailing growth and current valuation multiples.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Piramal_Pharma_a_good_buy_before_Q1_FY27_results\"><\/span><strong>Is Piramal Pharma a good buy before Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. Piramal Pharma is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_watch_in_Piramal_Pharmas_Q1_FY27_results\"><\/span><strong>What should investors watch in Piramal Pharma&#8217;s Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_Piramal_Pharma_share_price_live\"><\/span><strong>Where can I track Piramal Pharma share price live?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. Piramal Pharma share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Piramal Pharma Q1 Results FY27 preview: revenue and PAT estimates, results date, key catalysts, risks and share price target.<\/p>\n","protected":false},"author":35,"featured_media":139663,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-139231","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1783075202:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["80"],"rank_math_title":["Piramal Pharma Q1 FY27 Results Preview"],"rank_math_description":["Piramal Pharma Q1 Results FY27 preview: revenue estimate, PAT outlook, results date, key catalysts, risks and share price target based on trailing growth analysis."],"rank_math_focus_keyword":["Piramal Pharma Q1"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["139663"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["23357"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/Piramal-Pharma-Q1-Results-FY27.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/139231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=139231"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/139231\/revisions"}],"predecessor-version":[{"id":139672,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/139231\/revisions\/139672"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/139663"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=139231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=139231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=139231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}